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Las expectativas futuras de la interleukina (IL)-35

Esta es una revisión acerca del rol de IL-35, un nuevo miembro de la familia IL-12, en la respuesta inmunitaria contra infecciones parasitarias y bacterianas y de su rol beneficioso en reacciones auto inmunes, debido sus propiedades antiinflamatorias. Basándose en estudios de ratones
The interleukin-12 (IL-12) cytokine family contains IL-12, IL-23, IL-27, and IL-35 today. These four members are all heterodimeric cytokines, which are composed of one chain (p19, p28, or p35) and the other chain (p40 or Epstein-Barr virus induced gene 3 (EBI3)), and then signal through unique pairings of five receptor chains (IL-12Rβ1, IL-12Rβ2, IL-23R, gp130, and WSX-1) respectively. The latest identified IL-35 consists of two subunits: p35 and EBI3 4.6 . It is known that, to function correctly, the immune system must discriminate between endogenous and exogenous substances. When this discrimination fails, the immune system will destroy cells and tissues of the body, thus resulting in autoimmune diseases 7 . Regulatory T cells (Treg cells) actively suppress activation of the immune system and prevent pathological self-destruction, i.e. autoimmune disease. The critical role of Treg cells in the immune system was documented by the severe autoimmune syndrome that resulted from a genetic deficiency of Treg cells. In murine Treg cells, the defects in either p35 or EBI3 often lead to the loss of host immune suppression and bring in subsequent deterioration of immune diseases [8] [9] [10] . In this review, we emphasize on the significant findings about IL-35. These findings have important implications for the design of new therapeutic approaches in some intractable immune diseases such as Lupus Erythematosus and Diabetes Type 1.
The structure and receptor for IL-35
At first, the structure of IL-12 family member will only concisely be described here (Figure 1) 11 . 1) IL-12p70 is one type of heterodimeric cytokine consisting of p40 subunit and p35 subunit. While p35 subunit is structurally associated with type I cytokines, p40 subunit is homologous to the a-chain of soluble IL-6 receptor. The IL-12p70 receptor comprises IL-12Rβ1 chain and IL12-Rβ2 chain. p40 is also secreted as monomers or homodimers (IL-12p80) which then signals through IL-12Rβ1. 2) p19 protein was identified in terms of its homology with IL-6 or IL-12p35 12 and it was shown to interact with IL-12p40 subunit to form another type of heterodimeric cytokine known as IL-23. The IL-23 receptor consists of IL-12Rβ1 chain and another subunit termed IL-23R. 3) EBI3 has been identified as an IL-12p40 homologue, which was found to interact non-covalently with p28, another IL-12p35 homologue, thereby taking the shape of IL-27. The IL-27 receptor consists of WSX1 and gp130 (the latter is also a subunit of IL-6 receptor complex). 4) Recently, EBI3 was reported to interact with IL-12p35 to form the novel cytokine, termed IL-35, but the receptor for this heterodimeric cytokine remains unclear 13 . In terms of the homology of IL-35 with other IL-12 family members, some predictions about its receptor structure will be addressed here. 1) For IL-12, IL-12Rβ2 is expressed on activated T cells, whose expression could be stimulated by the agonists that promote the development of Th1 cells, or inhibited by the ones that promote the development of Th2 cells. Upon the interaction with its ligands, IL-12Rβ2 becomes tyrosine phosphorylated and provides binding sites for kinases such as Tyk2 and Jak2, which are important in activating critical transcription factors such as Stat4 in T cells or NK cells 14 . However, IL-12Rβ1 contains neither the N-terminal Ig-like activation domain, nor the cytoplasmic tyrosine residues required for docking and activating Stat4 15 . Thus, IL-12Rβ1 is mainly responsible for ligand interaction, not like IL-12Rβ2 as a signal transducer. 2) For IL-23, Jak2 and Stat3 transcription factors physically interact with IL-23R in a ligand-dependent manner and IL-23R itself could be tyrosine-phosphorylated upon the interaction with IL-23. Therefore, like IL-12Rβ2, IL-23R is mainly responsible for IL-23 signal transduction 16, 17 . 3) For IL-27, WSX1 directly binds to IL-27, but it cannot activate any signaling 18 . Surprisingly, WSX1 actually owns one tyrosine-based phosphorylation motif in the cytoplasmic domain, and the sequence of this domain closely resembles the Stat1 binding motif in the cytoplasmic region of IFN-γR, which selectively activates tyrosine phosphorylation of Stat1 19 . Contrasted with WSX1, gp130 leads to the intracellular activation of Src, Jak and Stat family members 20, 21, 22 . Based on the structural and functional similarity between IL-35 and other IL-12 family members, it is predicted that IL-35 receptor probably shares common features with the receptors for other IL-12 family members, in another word, the IL-35 receptor might consist of two subunits as well, one subunit mainly act as ligand interactor, and the other one mainly act as signal transducer. However, this remains to be further verified. ting the preferential secretion of EBI3-IL-12a (IL-35) by T cells. However, additional analysis of other haematopoietic populations suggested that there was still a significant but low expression of EBI3 or IL-12a in ad and CD8 + T cells. Myeloid differentiation primary-response gene 88 (MyD88), which is coupled to Toll-like receptor 4 (TLR4), leads to the activation of nuclear factorkB (NF-κB) (Figure 2 ), so as to induce the expression of relevant genes that encode interleukin-12 (IL-12) family members 23, 24 . Since IL-35 consists of p35 and EBI3, the expression of each one will be addressed here respectively. The expression of p35 could be regulated by multiple routes, as follows: Firstly, the interaction of MyD88 with IRF1 expands the expression of p35 gene 25 . Secondly, the TIR-domain-containing adaptor protein inducing IFN-β (TRIF) triggers the nuclear translocation of IRF3, which is then recruited to IFN-stimulated response element (ISRE) sites in the promoter regions of both p35 gene and IFN-β gene 26 . Next, IFN-β binds to the type I IFN receptor (IFNAR) and leads to the activation of IRF-7 that induces the expression of p35 gene 27 . Thirdly, upon the activation of TRIF-related pathway, IRF1 also enhances the expression of p35 gene 28, 29 . Moreover, the activation of p35 gene also requires the selective remodeling of nucleosomes to release it from the transcriptional suppression by Nuc2, because Nuc2 within the p35 promoter masks crucial ISRE-IRF-E and SP1 binding sites, like Nuc1 in the p40 promoter masks the transcription initiation site and CCAAT/ enhancer binding protein (C/ EBP) binding site [30] [31] [32] . On the other hand, EBI3 is regulated via MyD88 and NF-kB like p35, and the PU1 binding to ETS cis-regulatory element is another necessity for activating EBI3 promoter 33 . Moreover, some reports have already documented the induction of Foxp3 by stimulating conventional T cells in the presence of TGF-β [34] [35] [36] . Ethan M. Shevach, et al discovered that the induction of Foxp3 almost completely relied on the TGF-β present in the serum, which was markedly inhibited by the addition of anti-TGF-β antibodies to the cell cultures 37 . Besides this, as a downstream target of Foxp3, the expression of EBI3 was considerably increased in Foxp3-transduced Teff cells compared with control group, whereas Foxp3 only induced a limited expression of p35 38 . However, microarray analysis uncovered that Foxp3 regulated EBI3 indirectly, because it was not discovered within the Foxp3 direct target gene set 39 . 
The expression of IL-35
The biological functions of IL-35
IL-35 is required for the function of Treg cells
Some earlier reports documented that Treg cells exerted the immuno-suppressive function through their T-cell antigen receptors (TCR) 15, 16 . Next, researchers assessed how EBI3 and IL-12a mRNA levels in activated Treg cells were changed in the presence or absence of Teff cells 38 . Their results showed that both EBI3 and IL-12a mRNA were reduced significantly after the co-stimulation of anti-CD3 and anti-CD28, but were markedly upregulated together in Treg cells recovered from an in vitro Treg assay, which was coincided with the process of active suppression. While the loss of negative regulatory EBI3-IL-12a (IL-35) could be reversed by the loss of pro-inflammatory cytokines such as IL-27 and IL-12 in either EBI3-/-or IL-12a-/-mice respectively, those EBI3-/-mice were indeed more susceptible to leishmaniasis 18 . Likewise, those IL-12a-/-mice, differing from IL-12β-/-mice, were more susceptible to Helicobacter-induced colitis, Leishmania major infection, experimental autoimmune encephalomyelitis and collagen-induced arthritis 17, [19] [20] [21] . Treg cells have already been proven to control the homeostatic expansion of Teff cells in a lymphopenic, recombination activating gene 1 (Rag1)-/-environment 5, 22 . Moreover, researchers also assessed the ability of EBI3-/-or IL-12a-/-Treg cells to suppress the proliferation of wild-type Teff cells in vitro, and found that the immuno-suppressive capacity of EBI3-/-or IL-12a-/-Treg cells was markedly reduced, regardless of the population of Teff cells 38 . When purified wild-type Teff cells, either alone or in the presence of wild-type, EBI3-/-or IL-12a-/-Treg cells, were adoptively transferred into Rag1-/-mice by scientists, which subsequently confirmed that the expansion of wild-type Teff cells was hardly reduced in the presence of either EBI3-/-or IL12a-/-Treg cells compared with that in the presence of wild-type Teff cells, indicating that EBI3, together with p35 as a heterodimeric cytokine of IL-35, exerted the immuno-suppression synergistically. However, the latest report demonstrated that unlike murine Treg cells, ex vivo human Treg cells didn't express significant EBI3 mRNA, and p35 mRNA wasn't different between ex vivo Treg and Teff cells either, in other words, neither EBI3 nor p35 mRNA was affected by the over-expression of Foxp3 in human Treg cells, suggesting that IL-35 might not contribute to the suppressive mechanism of human Treg cells, contrasted with the results in murine counterparts 40 .
IL-35 is required for the anti-inflammatory responses
Due to the clinical importance of Treg in the control of rheumatoid arthritis (CIA), Wanda Niedbala, et al investigated the effects of IL-35 in the CIA model of DBA/1 mice [41] [42] [43] . Control group treated with PBS undoubtedly developed the expected disease progression. In contrast, mice treated with IL-35 displayed a significant reduction in the incidence and number of arthritic paws. Histological analysis showed that mice treated with PBS displayed mononuclear and poly-morphonuclear cell infiltration into the joint compartment, synovial hyperplasia, adjacent cartilage and bone erosion, but which were obviously reversed in the mice treated with IL-35, demonstrating that IL-35 potently suppressed the development of CIA, and such activity can prevent the progression of articular damage as well 44 . Serum of IL-35-treated mice contained significantly higher concentrations of IL-10 compared to the control group, and IL-10 could prevent NF-kB from initiating the transcription of relative genes that encode pro-inflammatory cytokines by inhibiting the activation of IKK and NF-kB's DNA binding capacities 45 . However, Lauren W et al discovered that Teff-derived IL-10 might also contribute to this regulatory milieu, because Treg co-cultures with IL-10 -/-Teff exhibited reduced suppression compared with wild type Teff 46 . On the other hand, severe IBD pathology, including loss of goblet cells mucus secretion, mucosal hyperplasia, extensive ulceration or infiltration of CD3 + T cells, remarkable transmural lymphohistiocytic inflammation, and destruction of the normal physiological functions by the inflammatory infiltration, was observed in the Treg-deleted recipients, but there was such a significant alleviation of the inflammation and CD3 + T-cell infiltration, as well as the regeneration of goblet cells and mucus secretion in wild-type Treg recipients 39, 47, 48 . Likewise, among IL-12 family members, IL-27 owns the similar immunosuppressive function requiring the activation of Stat1 and its downstream effector Socs3 49 . However, the anti-inflammatory mechanisms of IL-35 are still unclear. 55, 56 . In addition, there is one possible explanation that Treg cells could be synchronously triggered by IL-2 released from Teff cells 57 .
IL-35 suppressed the differentiation of Th17 cells
Recently, it was demonstrated that IL-35 markedly suppressed the differentiation of Th17 cells compared to the ones in medium alone 44 . Mangan group and Bettelli group discovered that TGF-β could promote pro-inflammatory responses through accelerating the differentiation of Th17 cells 58, 59 . Some researchers speculated that IFN-γ might inhibit the phosphorylation of TGF-β receptor's downstream effector Smad3, so as to block the TGF-β-induced differentiation of Th17 cells, while IFN-γ could be upregulated by IL-35 44, 60, 61 . Moreover, Th17 cells are characterized by the secretion of IL-17 and IL-22, in which IL-17 was regarded to be involved in host defense and protective immunity 62 ; IL-22 was considered to mediate IL-23-induced Th17 cell generation 63 ; and RORγt was found to be the key transcription factor for the differentiation of Th17 cells 64 . Meanwhile, the deletion of EBI3 could also upregulate the expression of IL-17, IL-22 and RORγt, thus confirming the immuno-suppressive effect of IL-35 on the differentiation of Th17 cells as well 65 .
However, the precise mechanism hidden behind this phenomenon requires further verification.
Conclusion and prospect
On the basis of present research, it was demonstrated that IL-35, as a novel member of interleukins, was required for the immunological capacity of Treg cells, and concomitant anti-inflammatory responses; it expanded not only CD4 + CD25
+ cells but also CD4 + CD25 -cells declaring its function in early anti-viral immune reactions; besides these, it could also abrogate the differentiation of Th17 cells like its homologue IL-27. However, French scientists published their surprising discovery not long ago; they reported that although CD3/CD28 stimulation induced low levels of EBI3 in various human CD4 + T cell subsets, no EBI3 could be detected in CD3/ CD28-stimulated human Treg cells behind its more biological activities requires to be further investigated. As our understanding of the IL-35 is rapidly growing and changing, it will bring us more therapeutic strategies towards some intractable immune diseases such as Diabetes Type 1 and Lupus Erythematosus.
